









市场行情
/
股票
/
nasdaq-akba
/

Akebia Therapeutics Inc

AKBA

1.660USD

-0.040-2.35%

收盘 12/26, 16:00（美东）报价延迟15分钟

440.28M总市值

亏损市盈率 TTM



Akebia Therapeutics Inc

1.660

-0.040-2.35%

概览公司财务分析

概览

公司

财务

分析

关于 Akebia Therapeutics Inc 公司

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Akebia Therapeutics Inc简介



公司代码AKBA

公司名称Akebia Therapeutics Inc

上市日期Mar 20, 2014

CEOButler (John P)

员工数量181

证券类型Ordinary Share

年结日Mar 20

公司地址245 First Street

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02142

电话16178712098

网址https://akebia.com/

公司代码AKBA

上市日期Mar 20, 2014

CEOButler (John P)

Akebia Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. John P. Butler

President, Chief Executive Officer, Director

1.68M

-17.18%

Mr. Adrian Adams

Independent Chairman of the Board

170.50K

+26.48%

Mr. Michael W. Rogers

Independent Director

131.73K

+37.18%

Ms. Cynthia Smith

Independent Director

130.93K

+37.49%

Dr. Steven C. Gilman, Ph.D.

Independent Director

122.83K

+40.97%

Dr. Myles Wolf, M.D.

Independent Director

103.38K

+52.75%

Ms. Leanne M. Zumwalt

Independent Director

79.40K

+81.69%

Mr. Nicholas (Nik) Grund

Senior Vice President, Chief Commercial Officer

45.48K

-89.72%

Mr. Erik Ostrowski

Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer

-100.00%

Dr. Steven K. Burke, M.D.

Senior Vice President - Research and Development, Chief Medical Officer

名称

名称/职务

职务

持股

持股变动

Mr. John P. Butler

President, Chief Executive Officer, Director

1.68M

-17.18%

Mr. Adrian Adams

Independent Chairman of the Board

170.50K

+26.48%

Mr. Michael W. Rogers

Independent Director

131.73K

+37.18%

Ms. Cynthia Smith

Independent Director

130.93K

+37.49%

Dr. Steven C. Gilman, Ph.D.

Independent Director

122.83K

+40.97%

Dr. Myles Wolf, M.D.

Independent Director

103.38K

+52.75%

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

6.30%

The Vanguard Group, Inc.

5.83%

State Street Investment Management (US)

4.46%

Geode Capital Management, L.L.C.

2.33%

Alerce Investment Management, L.P.

2.17%

其他

78.90%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

6.30%

The Vanguard Group, Inc.

5.83%

State Street Investment Management (US)

4.46%

Geode Capital Management, L.L.C.

2.33%

Alerce Investment Management, L.P.

2.17%

其他

78.90%

股东类型

持股股东

占比

Investment Advisor

20.87%

Investment Advisor/Hedge Fund

15.27%

Hedge Fund

7.16%

Research Firm

3.64%

Individual Investor

3.57%

Private Equity

2.18%

Bank and Trust

0.37%

Pension Fund

0.29%

Insurance Company

0.03%

其他

46.61%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

322

132.23M

46.40%

+1.48M

2025Q3

319

130.76M

46.38%

+15.12M

2025Q2

289

114.82M

39.60%

+12.72M

2025Q1

262

102.34M

28.68%

+27.30M

2024Q4

243

68.25M

29.95%

+8.53M

2024Q3

241

59.59M

29.67%

+2.86M

2024Q2

231

56.74M

30.94%

-537.20K

2024Q1

275

57.32M

33.03%

-11.84M

2023Q4

274

54.98M

40.78%

+1.55M

2023Q3

287

53.47M

42.97%

+287.09K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

16.58M

6.25%

+2.61M

+18.71%

Jun 30, 2025

The Vanguard Group, Inc.

14.61M

5.51%

+1.93M

+15.18%

Jun 30, 2025

State Street Investment Management (US)

8.00M

3.02%

+1.19M

+17.50%

Jun 30, 2025

Geode Capital Management, L.L.C.

6.07M

2.29%

+1.04M

+20.75%

Jun 30, 2025

Alerce Investment Management, L.P.

5.75M

2.17%

Dec 31, 2024

Satter Muneer A

5.75M

2.17%

+5.75M

Dec 31, 2024

Renaissance Technologies LLC

4.19M

1.58%

+188.60K

+4.71%

Jun 30, 2025

Morgan Stanley & Co. LLC

4.34M

1.64%

+2.26M

+108.33%

Jun 30, 2025

Qube Research & Technologies Ltd

1.71M

0.65%

+646.27K

+60.50%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Invesco Biotechnology & Genome ETF

1.9%

Invesco NASDAQ Future Gen 200 ETF

0.38%

State Street SPDR S&P Biotech ETF

0.26%

ALPS Medical Breakthroughs ETF

0.24%

First Trust Small Cap Growth AlphaDEX Fund

0.22%

Federated Hermes MDT Small Cap Core ETF

0.18%

Direxion Daily S&P Biotech Bull 3X Shares

0.16%

iShares Micro-Cap ETF

0.11%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.08%

Fidelity Enhanced Small Cap ETF

0.08%

Invesco Biotechnology & Genome ETF

占比1.9%

Invesco NASDAQ Future Gen 200 ETF

占比0.38%

State Street SPDR S&P Biotech ETF

占比0.26%

ALPS Medical Breakthroughs ETF

占比0.24%

First Trust Small Cap Growth AlphaDEX Fund

占比0.22%

Federated Hermes MDT Small Cap Core ETF

占比0.18%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.16%

iShares Micro-Cap ETF

占比0.11%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0.08%

Fidelity Enhanced Small Cap ETF

占比0.08%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Akebia Therapeutics Inc的前五大股东是谁？



Akebia Therapeutics Inc 的前五大股东如下：
BlackRock Institutional Trust Company, N.A.持有股份：16.58M，占总股份比例：6.25%。
The Vanguard Group, Inc.持有股份：14.61M，占总股份比例：5.51%。
State Street Investment Management (US)持有股份：8.00M，占总股份比例：3.02%。
Geode Capital Management, L.L.C.持有股份：6.07M，占总股份比例：2.29%。
Alerce Investment Management, L.P.持有股份：5.75M，占总股份比例：2.17%。